Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Home-treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: a Three-months, Pragmatic, Cluster Randomized, Open-label,Blinded Endpoint (PROBE) Trial

NCT05249790 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT05249790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05249790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Home-treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: a Three-months, Pragmatic, Cluster Randomized, Open-label,Blinded Endpoint (PROBE) Trial
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 3
Overall status
Withdrawn
Start date
February 24, 2022
Completion date
February 24, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19